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Asthma is a chronic inflammatory airway disease, with an array of cells involved in the pathogenesis. The role of 
neutrophils in asthma pathogenesis is controversial. This review highlights the mechanisms of neutrophils about 
their aberrant function in asthma and factors contributing to impaired response to corticosteroids, which may 
contribute to a better understanding of asthma pathogenesis and consequently, facilitate the development of 
novel strategies for managing and treating neutrophilia in asthma. 
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Asthma is a very common disease characterized by airway 
inflammation, reversible airway obstruction, airway 
hyperresponsiveness, and airway structural remodeling [1, 2]. 
Many types of cells, such as eosinophils, T lymphocytes, mast 
cells, neutrophils and dendritic cells (DCs) are involved in the 
pathophysiology of the airway inflammation in asthma. The 
role of T helper type 2 (Th2) lymphocytes, mast cells and 
eosinophils in the pathogenesis of asthma has been well 
established [3], but the role of neutrophils is controversial [4]. 
Previous studies demonstrated that severe asthma, persistent 
asthmatic status, acute asthma exacerbation, and 
corticosteroid-resistant asthma were associated  with 
increased numbers of neutrophils in peripheral blood and 
bronchoalveolar lavage fluid (BALF), sputum or bronchial 
biopsy samples [ 5 ,  6 ] .  There is increasing evidence  
demonstrated that neutrophils may involve in the 
development or exacerbation, and especially be associated 
with the severity of the disease [7, 8]. In this review, the 
authors discussed the aberrant function of neutrophils in the 
pathogenesis of airway inflammation in asthma. 
 
Aberrant function of neutrophil in asthma 
 
Neutrophils are the most abundant circulating 
polymorphonuclear leukocytes in human peripheral blood 
and play a fundamental role in the innate immunity [9]. They 
are recruited rapidly to sites of inflammation and initiate the 
inflammatory response, but they also actively participate in 
the resolution of inflammation. Their primary role is to kill 
invading bacteria and certain fungal species through 
phagocytosis by the release of preformed granular enzymes 
and proteins, and the production of a range of oxygen species. 
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Chemotaxis In the course of asthma, neutrophils infiltrate 
the airways and release many inflammatory mediators during 
early stage of asthma development [10]. That neutrophils 
migrating to airways is based on the reactivity of neutrophils 
to chemoattractive signals, known as chemotaxis which is 
crucial for an efficient control of pathogens [11]. The 
chemotactic activity of neutrophils induced by platelet 
activating factor (PAF) was greater in patients with asthma 
than in healthy subjects, which implied that neutrophils 
involved in the pathogenesis of asthma through their 
heightened recruitment into the bronchoalveolar lumen and 
the lung by local release of chemotactic factors [12]. Also, 
neutrophils from asthmatic patients exhibited increased 
chemotactic activity in the presence of homologous (pooled 
sera from healthy individuals) or autologous (patient’s own 
serum) serum compared with non-asthmatic controls. 
Autologous serum-induced neutrophil chemotaxis in patients 
with uncontrolled asthma was greater than controlled asthma 
[13]
.   This   phenomenon   could   be   explained by increased 
chemotactic factors, such as IL-8, TNFα, LTB4 and IL-17A, 
in the circulation of patients suffering from asthma [6, 14-17]. 
Our previous study also demonstrated that neutrophils from 
steroid-resistant asthma released more IL-8 at the presence of 
asthmatics serum, which might contribute to additional 
recruitment and activation of neutrophils in a positive 
feedback manner [18]. Moreover, Lavinskiene et al. reported 
that the migration of neutrophils to the airways after allergen 
challenge was increased in asthmatic comparing to non-
asthmatic subjects, because they were more sensitive to IL-8 
stimulation [19]. Though, a previous study indicated that 
neutrophils from mild asthmatic subjects exhibited impaired 
chemotaxis velocity in the presence of IL-8 and fMLP 
(formyl-methionyl-leucyl-phenylalanine) compared with 
non-asthmatic patients suffering from allergic rhinitis. And 
they identified neutrophil chemotaxis velocity as a sensitive 
marker for the discrimination between asthmatic and non-
asthmatic individuals presenting similar symptoms from 
airways [20]. The possibility to explain the impaired 
chemotactic response of neutrophils might be the different 
methods, microfluidic chip and automated readout method as 
shown in their study [20]. The increased migration of 
neutrophils into the airways stimulates the accumulation and 
abnormal activation of inflammatory cells, which are largely 
responsible for oxidative stress and production of proteases 
and inflammatory cytokines contributing to lung injury and 
chronic inflammation [21, 22]. 
 
Phagocytosis Neutrophils have long been considered as 
phagocytes whose main purpose is to engulf and degrade 
microorganisms. The reduced ability of alveolar 
macrophages from subjects with COPD to phagocytose 
 
apoptotic bronchial epithelial cells contributed to secondary 
necrosis of the uncleared material and perpetuation of 
inflammation [23]. And in non-eosinophilic asthma, the 
persistent airway neutrophilia and chronic inflammation were 
due to the impaired efferocytosis of macrophage [23]. It has 
been demonstrated that neutrophilic phagocytosis in 
asthmatic children was defective either when triggered via 
pattern recognition receptors or mediated by complement and 
immunoglobulin receptors. Moreover, short-term 
corticosteroid treatment (3–6 months) was insufficient in 
restoring proper phagocytic function of neutrophils [24]. 
Though phagocytic activity was increased after challenge in 
patients with asthma, it was still not sufficiently effective [19]. 
The significant decrease in phagocytosis of neutrophils 
shown in asthma contributed to the progression of late-phase 
allergen-induced airway inflammation [19, 25]. 
 
ROS Release of the reactive oxygen species (ROS) in the 
mechanism of respiratory burst is one of the main functions  
of neutrophils. Neutrophils recruited by allergen challenge 
generate sustained ROS in the airways, which may promote 
allergic inflammation through ROS generation [26].  The 
effects of reactive oxygen species in asthma include 
decreased beta-adrenergic function in lungs, airway smooth 
muscle contraction, increased vascular  permeability, 
bronchial hyperresponsiveness, increased mucus secretion, 
impaired ciliary activity, generation of chemotactic factors 
and lipid peroxidation, and secondary production of  
mediators with a bronchoconstrictor effect [27]. It has been 
demonstrated that neutrophils purified from 
bronchoalveolarlavage fluid and peripheral blood from 
patients with allergic asthma released significantly higher 
quantities of ROS compared to healthy individuals [13, 19, 27-29]. 
In mice mode of asthma, the gp91phox deficiency mice, the 
dominant superoxide generating enzyme in neutrophils, had 
decreased ROS production, and attenuated allergic 
inflammatory response to allergen challenge [30]. Activated 
neutrophils in allergic patients cause the subsequent release  
of intracellular toxic oxidants and enzymes, which in turn 
activate proteases leading to more intensive ROS production. 
And intensive ROS production activates redox-sensitive 
signaling cascades, stimulates production of proinflammatory 
cytokines, and promotes inflammation and lung damage [19]. 
 
Neutrophil extracellular traps Recently, it is discovered 
that neutrophils are able to release their nuclear DNA in the 
form of neutrophil extracellular traps, known as NETs. 
Neutrophil extracellular traps production results from the 
extracellular release of decondensed chromatin, histones and 
granular proteins from neutrophils activated by various 
stimuli including cytokines (e.g. IL-8 or TNF-a), PMA, 
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lipopolysaccharide (LPS), or microbial proteins [31, 32]. NETs 
are an important component of innate immunity, but their  
role is ambiguous as causing severe host tissue damage in 
certain pathological conditions [33]. Accumulating evidences 
shown that NETs directly contributed to host cell death and 
chronic tissue damage when formed in excess or were 
insufficiently cleared by mechanisms that were still poorly 
understood [34]. Recently, several studies have detected 
increased NETs and NET components in neutrophils from 
airways or peripheral blood of patients with asthma, 
suggesting an involvement of NETs in asthma pathogenesis 
[35-37]
.  Accumulation  of  excessive  NETs  contributed  to the 
persistent airway neutrophilia and enhanced asthma severity 
by damaging airway epithelium and triggering inflammatory 
responses of human airway epithelial cells and eosinophils 
[35]
. Thus further study should emphasize on elucidating the 
exact role that NETs are playing in asthma, and illuminating 
whether regulation of neutrophil activation or NETs 
formation will offer therapeutic benefit to patients. 
 
Involvement of neutrophils in airway inflammation of 
asthma 
 
The role of neutrophils is ambiguous in the pathology of 
asthma. Abundant studies reported that airway neutrophilic 
inflammation was associated with asthma phenotypes/ 
endotypes, severe asthma, asthma exacerbations, and 
corticosteroid treatment responses [38]. 
 
Phenotype Neutrophils are one of the most inflammatory 
cells in airway. Based on the proportions of neutrophils and 
eosinophils in sputum are the criteria for pathologic 
phenotype of asthma. Subjects with increased eosinophils in 
sputum are eosinophilic asthma; neutrophilic asthma are 
based on raised sputum neutrophils above a defined cut-off 
level and paucigranulocytic asthma are those with normal 
numbers of both eosinophil and neutrophil in airways; In 
addition, some individuals have a mixed type of 
inflammation, mixed granulocytic asthma ,when there is 
sputum neutrophilia and eosinophilia [39]. Cut-off levels used 
to define sputum eosinophilia were various in different 
researches as follows: >1.01% [39], >2% [40]，≥2% [41], or ≥3% 
[42]
, but a ≥ 3% cut-off was reported to be the most precise 
value to identify airway eosinophilia [43]. The cut-off for 
sputum neutrophilia has not been clearly established with a 
wide range of values: >40% [44], ≥50% [45],> 61% [46], or 
≥76%[47]. 
 
Severity and airflow obstruction The neutrophils may 
contribute to the pathophysiology of severe asthma since 
increased neutrophilic inflammation in induced sputum and 
in the bronchial submucosa has been reported in such 
patients [48-51]. The persistent neutrophilic airway 
inflammation is associated with fixed airflow obstruction [49]. 
The relationship between neutrophilic airway inflammation 
and progressive airflow obstruction is biologically plausible 
because neutrophils can secrete a variety of inflammatory 
factors including cytokines, proteases, and lung parenchymal 
reactive oxygen species that can cause mucus hypersecretion 
and airway damage [52]. Several researches shown that 
sputum total neutrophil counts were associated with reduced 
lung function and based on this finding it has been speculated 
that airway neutrophils might involve in the pathophysiology 
of irreversible airflow obstruction in asthma [52, 53]. Therefore, 
neutrophils are increased in the airways of severe asthma, 
and may contribute to refractory disease. 
 
Glucocorticoids use Glucocorticoids (GCs) are the most 
effective drugs for the treatment of asthma. It has been 
proposed that airway neutrophilia seen in asthma might be 
due to corticosteroid treatment for the function of promoting 
neutrophil survival by inhibiting their apoptosis [54-56]. 
However, a study by Hastie et al. demonstrated that 
corticosteroid treatment had no effects on sputum cell counts 
suggesting minimal effects of continuous corticosteroids 
exposure on sputum granulocytes [57]. Another study on 
severe asthma subjects shown that there was no statistical 
difference in sputum neutrophilia between subjects on high 
dose inhaled or chronic oral corticosteroids even though the 
subjects stratified by intensity of corticosteroid exposure [44]. 
The persistent neutrophilia in asthma should not own to the 
use of glucocorticoids, because glucocorticoids exerted the 
same effects on the apoptosis of neutrophils from steroid-
sensitive asthma and steroid-resistant asthma with increased 
neutrophils in airway, as shown in our study [18]. In addition, 
Uddin and colleagues indicated that unresolved airways 
neutrophilia in severe asthma were the result of their 
prolonged survival promoted by factors released by 
inflammatory and structural cells of the airways [58]. So, 
airway neutrophilia in asthma may be a manifestation of the 
disease itself rather than the result of treatment with high-
dose corticosteroids. 
 
Exacerbation Up to 80% of exacerbations in adults with 
asthma were associated with sputum neutrophilia, although 
the predominant sputum cell type could alter during 
successive exacerbations [59-62]. The causes of asthma 
exacerbations are numerous including viruses, allergens (dust 
mite, pollen, animal dander), occupational exposures (grains, 
flours, cleaning agents, metals, irritants, woods), hormones 
(menstrual asthma), drugs (ASA, NSAIDs, beta-blockers), 
exercise, stress, and air pollutants. But viruses were detected 
Inflammation & Cell Signaling 2019; 6: e1535. doi: 10.14800/ics.1535; ©  2019 by Meijia Wang, et al. 
www.smartscitech.com/index.php/ics 





in airway secretions in most of the cases [63]. It is widely 
recognized that the neutrophilia might be the consequence of 
a virus infection leading to the acute exacerbation. Some 
studies have confirmed that predominant neutrophils in the 
sputum of patients with acute asthma exacerbation were due 
to respiratory tract infection [64, 65]. However, neutrophils in 
asthma exacerbations are also due to causes other than 
infection. Increased neutrophil counts were observed in 
bronchial lavage fluid of patients with noninfectious acute 
exacerbations [66]. Dominant neutrophilic inflammation in 
adults with acute asthma cannot be explained by infection, 
since C. pneumoniae, a potential cause of asthma 
exacerbation and neutrophilic inflammation was not detected 
in almost all samples [67]. Initial increased neutrophils, 
interestingly, continued to increase throughout resolution of 
the exacerbation, which reminded that neutrophil might have 
roles in both the initiation and resolution of attacks [68]. 
 
There have been limited effective methods to specifically 
detect whether neutrophils in airways were a distinct 
pathophysiological characteristic or the result of other factors, 
such as glucocorticoids, infection. 
 
Factors of insensitive to corticosteroids in neutrophilia 
 
Neutrophils are generally considered to be less responsive 
to GCs, since events involved in neutrophil activation, 
including adherence, chemotaxis, degranulation, and 
arachidonic acid metabolite release are not effectively 
inhibited by glucocorticoids [69]. In the course of asthma, 
neutrophilic inflammation is associated with an impaired 
therapeutic response to corticosteroids [70, 71]. It is unknown if 
the neutrophils themselves contribute to the relative steroid 
insensitivity or if this is determined by the mechanisms that 
lead to the recruitment of neutrophils in asthma [72]. Previous 
studies about the mechanisms of glucocorticoid insensitivity 
were focused on decreased binding affinity of the 
glucocorticoid receptor (GR) and translocation, increased 
expression of the alternatively-spliced variant GR-β, 
increased binding of the activated GR receptor to pro-
inflammatory transcription factors such as AP-1 and reduced 
recruitment of histone deacetylase and so on [73, 74]. And 
those in their researches are mostly other cell types, such as 
peripheral blood mononuclear cells [75-77], alveolar 
macrophages [78-80], or monocytes [81, 82]. These factors also 
exerted critical effect on the impaired response to 
glucocorticoid in neutrophilia. 
 
Increased GR-β expression The effects of GC are 
mediated by the GC receptor (GR) - α, which represses 
expression of various genes encoding inflammatory  
mediators [83, 84]. In addition to GR-α, GR-β functions as a 
putative dominant negative form of GR-α by forming 
heterodimers with it to impair steroid sensitivity [85-88]. A 
variety of pro-inflammatory cytokines were found to enhance 
the expression of GR-β such as TNF-α, IFN-γ, interleukin 1 
(IL-1), IL-2 and IL-4 in combination, IL-17/IL-23 and IL-13 
[85-87,  89,  90]
.  High  levels  of  GR-β  have  been  reported  in 
neutrophils, and these may be upregulated by IL-8. These 
data suggests that the inflammatory environment in itself 
may increase neutrophil insensitivity by increasing the ratio 
of GR-β to GR-α, and promoting further heterodimer 
formation [91]. It has not been proved whether other cytokines 
could improve the expression of GR-β or not. The intensive 
expression of GR-β contributed to neutrophil insensitivity. 
And strategies aimed at reducing expression of GR-β in 
neutrophils may provide a starting point for the development 
of novel anti-inflammatory treatments for neutrophil-
associated disease. 
 
Abnormal histone acetylation Histone acetylation plays a 
critical role in the regulation of inflammatory genes and the 
mechanism of action of glucocorticoids [92]. The anti-
inflammatory actions of glucocorticoids are partly related to 
the recruitment histone deacetylase-2 (HDAC2) activated by 
glucocorticoid receptors (GR), which inhibits the activation 
of inflammatory genes by the transcription factor nuclear 
factor-κ B (NF-κ B) [93]. Reduced HDAC2 activity has been 
reported in numerous glucocorticoid-insensitive diseases [94]. 
A recent research focused on abnormal histone acetylation of 
neutrophils shown that impaired nuclear recruitment of 
histone deacetylase-2 (HDAC2) could be an important 
mechanism of steroid resistance of the neutrophilic 
inflammation in exacerbations of asthma, which led to 
continuing enhanced expression of neutrophil 
chemoattractants and survival factors [95]. Additionally, 
oxidants in the airways of asthmatic patients generated by 
oxidative stress were due to the formation of peroxynitrite, 
tyrosine nitration, and lipid peroxidation, which could 
decrease the activity of HDAC2 via the nitration of tyrosine 
residues in HDAC2 [96]. Tyrosine nitration of HDAC2 is an 
important mechanism of steroid resistance [97]. These studies 
suggest that abnormal histone acetylation is an important 




Neutrophils play a critical role in the inflammatory and 
immune responses by the virtue of their ability to produce a 
variety of cytokines. Though, Hirsch and colleagues reported 
that glucocorticoids exerted similar genomic effects on  
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neutrophils and on other blood leukocytes by quantifying the 
effect of glucocorticoids on LPS-induced pro-inflammatory 
mRNA expression in neutrophils and neutrophil-depleted 
leukocytes [98]. In our recent study, dexamethasone exerted 
impaired anti-inflammatory action on neutrophils from 
steroid-resistant asthma at the present of atopic asthmatic 
serum, a mimic of asthmatic milieu, by showing that the 
inhibition of IL-8 production by dexamethasone in steroid-
resistant asthma was less when compared to steroid-sensitive 
asthma [18]. Similarly, a previous study on blood neutrophils 
in severe asthma shown that oxidative burst stimulated by 
phorbol myristate acetate (PMA), and the release of IL-8 
which represented the activation of neutrophils, were not 
inhibited by oral corticosteroids [99]. Those data indicated that 
impaired function of glucocorticoids on neutrophils to 
repress pro-inflammation cytokine in some condition might 
be important in the pathogenesis of severe steroid-resistant 
asthma. 
 
The importance of TH17 cells in neutrophilic 
inflammation lies in the ability of IL-17 to induce 
granulopoiesis, neutrophil chemotaxis, and the anti-apoptotic 
property of G-CSF [100, 101]. Accumulating evidences suggest 
a correlation between high levels of IL-17 and steroid-
resistant disease [102]. In mice, TH17 cell-mediated airway 
inflammation and AHR are steroid resistant [103]. IL-17A, a 
crucial inflammatory cytokine produced by Th17 cells, 
induces a glucocorticoid resistance in human airway 
epithelial cells, which is mediated by PI3K activation and 
subsequent reduction of HDAC2 activity [104]. The role of IL-
17 in glucocorticoid resistance is also associated with the 
expression of GR-β in airway epithelial cells, which is not 
suppressed by glucocorticoids in-vitro [105]. Recently, a 
research by Murcia and colleagues demonstrated that 
activation and increased survival of equine neutrophils 
induced by IL-17 was insensitive to glucocorticoids [106]. So, 
glucocorticoid resistance induced by Th17 cells may be an 





As mentioned above in this review, NETs are associated 
with inflammation and disease severity in chronic airway 
diseases [34, 35]. While glucocorticoid had no effect on the 
NETs formation in peripheral blood neutrophils induced by 
activation, phorbol myristate acetate (PMA), in vitro [107]. 
Decreased phagocytosis in neutrophils did not return to 
normal after corticosteroid treatment [24], because 
corticosteroids decrease the phagocytosis which has been 
seen in monocytes with decreased phagocytosis  and 
repression the release of inflammatory cytokines by 
corticosteroids [108, 109]. Asthmatic milieu impedes the anti-
inflammatory of glucocorticoid in steroid resistant asthma [18]. 
Macrophage migration inhibitory factor (MIF) is an 
immunologic regulator that has anti-glucocorticoid effects 
[110]
.  It  is  induced  by  glucocorticoids  and  inhibits  their 
anti-inflammatory effects, by inhibiting the induction of 
MKP-1. MIF has been implicated in the pathogenesis of 
allergic inflammation in mouse models of asthma and in 
severe asthma [111, 112]. 
 
Conclusion and future directions 
 
No matter whether neutrophilia in asthma is due to 
corticosteroids, chronic pulmonary infection, delayed 
neutrophil apoptosis, or the alternative pathology of 
asthma .The role of neutrophils in the development of asthma 
is crucial. And their presence may be associated with 
increased asthma severity. Alterations in neutrophil functions 
lead to ineffective removal of pathogens and increased 
inflammation [19]. Hence, novel targeted medications must be 
developed that could control neutrophilic inflammation and 
still maintain their antibacterial/anti-fungal properties, thus 
allowing individuals to maintain effective innate immune 
responses to invading pathogens. Further development of 
strategies that emphasize on factors leading to insensitive 
responsiveness to glucocorticoid in neutrophilia may increase 
the efficacy of glucocorticoid therapy in asthmatic patients 
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